June 17, 2015
Sumitomo Mitsui Banking Corporation
Sumitomo Mitsui Finance and Leasing Company, Limited
The Japan Research Institute, Limited
Agreement to Conclude Memorandum of Understanding with China National Pharmaceutical Group Corporation
TOKYO, June 17, 2015----Sumitomo Mitsui Banking Corporation (SMBC, President & CEO: Takeshi Kunibe), Sumitomo Mitsui Finance and Leasing Company, Limited (SMFL, President & CEO: Yoshinori Kawamura), and The Japan Research Institute, Limited (JRI, President & CEO: Masahiro Fuchizaki) announced today an agreement to conclude a Memorandum of Understanding with China National Pharmaceutical Group Corporation (“Sinopharm”, President: Lulin She) for the purpose of enhancing mutual cooperation in the medical and healthcare field.
Sinopharm is the largest medical and healthcare group in China, directly managed by State-owned Assets Supervision and Administration Commission of the State Council, with the core businesses of distribution, logistics, retail, scientific research and manufacture of healthcare related products.
We will leverage this partnership with Sinopharm to enhance our operations and further support our clients in Japan planning to operate and invest in the Chinese medical and healthcare industry. SMBC will strengthen its business platform and grow its business by providing enhanced services, including accelerating the number of business matching events. SMFL, which leases medical equipment through its Chinese subsidiary, sees a great potential for growth in this market. JRI will strengthen and grow its consulting business platform and business through the corporation with Sinopharm, among others, using methodologies in Japan, the fastest aging country in the world with its birthrate among the lowest, for addressing medical and healthcare issues.
Profile of Sinopharm
Name: China National Pharmaceutical Group Corporation
Year of Establishment: 1998
Address: No.20 Zhichun Road, Haidian District, Beijing, China